MacroChem to Present at the Equities Magazine Discovery Day Corporate Conference December 1, 2006

Wellesley Hills, Massachusetts, November 28 (ots/PRNewswire) -

MacroChem's (OTC Bulletin Board: MACM) president and CEO, Robert
DeLuccia, will present at the upcoming Equities Magazine Discovery
Day Corporate Conference at the Yale Club in New York City on
December 1, 2006. Mr. DeLuccia is scheduled to present at 11:25 AM
EST.

The Equities Corporate Conference is an all day event featuring
special presentations from 12 emerging public company CEOs. The
conference provides an opportunity for promising emerging growth
companies to connect with the investment community. Interested
parties can access a live audio webcast of the Company's
presentation, through a link at http://www.equitiesmagazine.com. The
presentation will be available for 90 days.

About MacroChem

MacroChem Corporation is a specialty pharmaceutical company with
two clinical development stage products containing our patented
enhancer, SEPA(R): EcoNail, to treat fungal infection of the nail and
Opterone(R), to treat male hypogonadism. In addition to our SEPA
technology, we are also evaluating applications for MacroDerm(TM),
our patented series of polymers that impede penetration of active
ingredients through the skin. For more information visit our website,
http://www.macrochem.com.

About Equities Magazine

Equities magazine is focused on bringing together corporate
executives and corporate and institutional investment professionals
who closely follow and invest in mid cap and small cap growth
companies. Equities corporate conferences now celebrate 25 years of
bridging the gap between emerging public companies and the investment
community.

Forward-Looking Statements

With the exception of historical information contained in this
press release, the matters described herein are forward-looking
statements that involve risks and uncertainties. MacroChem's actual
results may differ significantly from the results discussed in the
forward-looking statements. Factors that might cause such a
difference include, but are not limited to, those discussed or
referred to in the section entitled "Risk Factors" in MacroChem's
Annual Report on Form 10-K, as well as those discussed elsewhere
therein, and include, without limitation, risks regarding product
development, the timing and results of clinical trials, the
regulatory approval process, capital requirements, financial
condition, patent protection and dependence on third parties for
development and licensing arrangements. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date hereof. MacroChem undertakes no obligation to
update publicly any forward-looking statements, whether as a result
of new information, future events or otherwise. For more information
visit our website, http://www.macrochem.com.

Contact:
MacroChem Corp.: Bernard Patriacca - VP/CFO
+1-781-489-7310
Investor Relations: The Investor Relations Group, Inc.
Jordan Silverstein/Christine Berni
+1-212-825-3210
Web site: http://www.macrochem.com
http://www.equitiesmagazine.com

ots Originaltext: MacroChem Corporation
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Bernard Patriacca, VP� of MacroChem Corporation, +1-781-489-7310;
or Jordan Silverstein or Christine Berni, both of The Investor
Relations Group, Inc., +1-212-825-3210, for MacroChem Corporation